

Daniel D De Carvalho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6497754/publications.pdf>

Version: 2024-02-01

74
papers

8,711
citations

109264

35
h-index

95218

68
g-index

102
all docs

102
docs citations

102
times ranked

15593
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. <i>Cell</i> , 2015, 162, 961-973.	13.5	1,075
2	Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer. <i>Cancer Cell</i> , 2014, 26, 577-590.	7.7	959
3	Epigenetic modifications as therapeutic targets. <i>Nature Biotechnology</i> , 2010, 28, 1069-1078.	9.4	686
4	Sensitive tumour detection and classification using plasma cell-free DNA methylomes. <i>Nature</i> , 2018, 563, 579-583.	13.7	624
5	LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. <i>Cell</i> , 2018, 174, 549-563.e19.	13.5	473
6	TGF- β 2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. <i>Nature Communications</i> , 2018, 9, 4692.	5.8	388
7	Epigenetic therapy in immune-oncology. <i>Nature Reviews Cancer</i> , 2019, 19, 151-161.	12.8	345
8	DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival. <i>Cancer Cell</i> , 2012, 21, 655-667.	7.7	240
9	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. <i>Nature Cell Biology</i> , 2021, 23, 87-98.	4.6	209
10	DNA methylation and cellular reprogramming. <i>Trends in Cell Biology</i> , 2010, 20, 609-617.	3.6	193
11	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	7.7	191
12	Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. <i>Nature Medicine</i> , 2020, 26, 1044-1047.	15.2	170
13	Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. <i>Cancer Cell</i> , 2016, 30, 337-348.	7.7	166
14	Polycomb-Repressed Genes Have Permissive Enhancers that Initiate Reprogramming. <i>Cell</i> , 2011, 147, 1283-1294.	13.5	161
15	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , 2020, 26, 1041-1043.	15.2	161
16	Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency. <i>Nature</i> , 2020, 588, 169-173.	13.7	149
17	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. <i>Cancer Cell</i> , 2019, 35, 782-797.e8.	7.7	143
18	IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment. <i>Cancer Research</i> , 2015, 75, 3788-3799.	0.4	140

#	ARTICLE	IF	CITATIONS
19	Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. <i>Nature Immunology</i> , 2018, 19, 571-582.	7.0	137
20	Nucleolar RNA polymerase II drives ribosome biogenesis. <i>Nature</i> , 2020, 585, 298-302.	13.7	135
21	Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. <i>Nature Protocols</i> , 2019, 14, 2749-2780.	5.5	118
22	OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14497-14502.	3.3	117
23	A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. <i>Nature Communications</i> , 2019, 10, 19.	5.8	113
24	Nucleosomes Containing Methylated DNA Stabilize DNA Methyltransferases 3A/3B and Ensure Faithful Epigenetic Inheritance. <i>PLoS Genetics</i> , 2011, 7, e1001286.	1.5	103
25	GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. <i>Science Immunology</i> , 2019, 4, .	5.6	85
26	Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1312-1329.	7.7	84
27	The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 31-43.	3.6	79
28	Symmetrical Dose-Dependent DNA-Methylation Profiles in Children with Deletion or Duplication of 7q11.23. <i>American Journal of Human Genetics</i> , 2015, 97, 216-227.	2.6	65
29	Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis. <i>Cancer Discovery</i> , 2021, 11, 2707-2725.	7.7	65
30	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
31	Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer. <i>Trends in Cancer</i> , 2018, 4, 583-597.	3.8	53
32	Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4230-4244.	3.2	53
33	DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells. <i>Molecular Cell</i> , 2021, 81, 1469-1483.e8.	4.5	52
34	The Transition from Quiescent to Activated States in Human Hematopoietic Stem Cells Is Governed by Dynamic 3D Genome Reorganization. <i>Cell Stem Cell</i> , 2021, 28, 488-501.e10.	5.2	51
35	BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. <i>Oncogene</i> , 2011, 30, 223-233.	2.6	45
36	SNF5 Is an Essential Executor of Epigenetic Regulation during Differentiation. <i>PLoS Genetics</i> , 2013, 9, e1003459.	1.5	43

#	ARTICLE	IF	CITATIONS
37	PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. <i>Nature Chemical Biology</i> , 2022, 18, 821-830.	3.9	43
38	Clinical advances in targeting epigenetics for cancer therapy. <i>FEBS Journal</i> , 2022, 289, 1214-1239.	2.2	42
39	Mapping the cellular origin and early evolution of leukemia in Down syndrome. <i>Science</i> , 2021, 373, .	6.0	42
40	Reactivation of Endogenous Retroelements in Cancer Development and Therapy. <i>Annual Review of Cancer Biology</i> , 2020, 4, 159-176.	2.3	36
41	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
42	Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities. <i>Journal of Cell Biology</i> , 2018, 217, 2951-2974.	2.3	35
43	Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. <i>Nature Communications</i> , 2019, 10, 1436.	5.8	33
44	O-Acetylation of Peptidoglycan Limits Helper T Cell Priming and Permits <i>Staphylococcus aureus</i> Reinfection. <i>Cell Host and Microbe</i> , 2017, 22, 543-551.e4.	5.1	32
45	The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids. <i>Cell Stem Cell</i> , 2019, 24, 621-636.e16.	5.2	32
46	Early-life antibiotic treatment enhances the pathogenicity of CD4+ T cells during intestinal inflammation. <i>Journal of Leukocyte Biology</i> , 2017, 101, 893-900.	1.5	31
47	High-throughput DNA analysis shows the importance of methylation in the control of immune inflammatory gene transcription in chronic periodontitis. <i>Clinical Epigenetics</i> , 2014, 6, 15.	1.8	28
48	Epigenetic regulation of nitric oxide synthase 2, inducible (Nos2) by NLRC4 inflammasomes involves PARP1 cleavage. <i>Scientific Reports</i> , 2017, 7, 41686.	1.6	26
49	The role of DNA-demethylating agents in cancer therapy. , 2020, 205, 107416.		26
50	Pharmacological DNA demethylation: Implications for cancer immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1090077.	2.1	23
51	Pre-neoplastic epigenetic disruption of transcriptional enhancers in chronic inflammation. <i>Oncotarget</i> , 2016, 7, 15772-15786.	0.8	23
52	Aberrant DNA methylation reprogramming during induced pluripotent stem cell generation is dependent on the choice of reprogramming factors. <i>Cell Regeneration</i> , 2014, 3, 3:4.	1.1	22
53	DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma. <i>Neuro-Oncology</i> , 2022, 24, 442-454.	0.6	21
54	H3K9 methylation drives resistance to androgen receptor antagonist therapy in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114324119.	3.3	21

#	ARTICLE	IF	CITATIONS
55	Cell-free DNA as a post-treatment surveillance strategy: current status. <i>Seminars in Oncology</i> , 2017, 44, 330-346.	0.8	20
56	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	1.3	20
57	Spliceosome-Targeted Therapies Induce dsRNA Responses. <i>Immunity</i> , 2021, 54, 11-13.	6.6	19
58	Mitochondrial carrier homolog 2 is necessary for AML survival. <i>Blood</i> , 2020, 136, 81-92.	0.6	19
59	BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. <i>Cell Death and Disease</i> , 2017, 8, e3114-e3114.	2.7	15
60	Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. <i>Epigenomics</i> , 2020, 12, 1317-1332.	1.0	15
61	Constitutive Androstane Receptor Ligands Modulate the Anti-Tumor Efficacy of Paclitaxel in Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e99484.	1.1	13
62	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. <i>Cancer Discovery</i> , 2022, 12, 1560-1579.	7.7	13
63	The next generation of DNMT inhibitors. <i>Nature Cancer</i> , 2021, 2, 1000-1001.	5.7	11
64	DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5729-5731.	3.2	9
65	The Cell Wall Fraction from <i>Fonsecaea pedrosoi</i> Stimulates Production of Different Profiles of Cytokines and Nitric Oxide by Murine Peritoneal Cells In Vitro. <i>Mycopathologia</i> , 2010, 170, 89-98.	1.3	6
66	Methods to detect endogenous dsRNA induction and recognition. <i>Methods in Enzymology</i> , 2019, 629, 35-51.	0.4	4
67	Drug-induced activation of "junk" DNA - A path to combat cancer therapy resistance?. <i>Oncoscience</i> , 2017, 4, 115-116.	0.9	4
68	Identification of the global miR-130a targetome reveals a role for TBL1XR1 in hematopoietic stem cell self-renewal and t(8;21) AML. <i>Cell Reports</i> , 2022, 38, 110481.	2.9	4
69	Abstract LB-179: Integrated (epi)genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. , 2016, , .		1
70	Using epigenetic data to estimate immune composition in admixed samples. <i>Methods in Enzymology</i> , 2020, 636, 77-92.	0.4	0
71	Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential. <i>STAR Protocols</i> , 2021, 2, 100549.	0.5	0
72	Abstract B56: DNA demethylation in gene bodies is of therapeutic significance. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
73	Abstract PR07: SNF5 is an essential executor of epigenetic regulation during differentiation. , 2013, , .		0
74	DNA-Demethylating Agents Enhance Cytolytic Activity of CD8 T Cells and Anti-Tumor Immunity. SSRN Electronic Journal, 0, , .	0.4	0